DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Tuesday. The firm issued a hold rating on the stock.

A number of other research firms also recently weighed in on DBVT. HC Wainwright upped their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a report on Tuesday, December 10th.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $3.04 on Tuesday. The company’s 50-day moving average is $3.42 and its 200 day moving average is $3.97. The stock has a market capitalization of $62.53 million, a P/E ratio of -0.68 and a beta of 0.64. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $10.70.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.